What the study found
The case report describes a 69-year-old man whose previously stable, untreated pulmonary tuberculous focus was reactivated after chemoimmunotherapy with tislelizumab, an immune checkpoint inhibitor. After he stopped anti-tuberculosis treatment early, the reactivated lesion regressed back to its original size, and both the tuberculous focus and lung cancer remained stable at 10 months.
Why the authors say this matters
The authors say the case suggests that a short course of anti-tuberculosis therapy, aimed at lowering bacterial load, may be a workable way to manage immune checkpoint inhibitor-related reactivation of latent tuberculosis infection. They conclude this may help patients continue immune checkpoint inhibitor treatment safely, and they note that this scenario challenges the usual requirement for a full anti-tuberculosis course.
What the researchers tested
This was a single-patient case report. The patient had stage IV lung squamous cell carcinoma and a long-term radiologically stable pulmonary tuberculous focus, then received paclitaxel, carboplatin, and tislelizumab; the tuberculous reactivation was confirmed by next-generation sequencing.
What worked and what didn't
The malignant mass regressed after four cycles of chemoimmunotherapy. Anti-tuberculosis therapy was complicated by severe synergistic toxicity with chemotherapy, and the patient self-discontinued after two months; despite not completing a full anti-TB course, the reactivated granulomatous lesion regressed to baseline and both lesions stayed stable at 10 months.
What to keep in mind
This is a single case, so the findings cannot establish a general treatment rule. The abstract does not describe broader limits beyond the toxicity problem and the lack of consensus for managing immune checkpoint inhibitor-activated tuberculosis.
Key points
- A stable, untreated pulmonary tuberculous focus reactivated after chemoimmunotherapy including tislelizumab.
- Next-generation sequencing confirmed the tuberculous reactivation.
- Anti-tuberculosis treatment was stopped after two months because of severe synergistic toxicity with chemotherapy.
- The reactivated granulomatous lesion regressed to its original baseline size without a complete anti-TB course.
- At 10 months, both the tuberculosis lesion and the lung cancer remained stable.
Disclosure
- Research title:
- Short-course anti-TB therapy followed regression of reactivated TB focus
- Authors:
- Xiao-Jun Guo, Rui Ma, Yanling Ma, Shaopeng Hua
- Institutions:
- Qinghai No.3 People's Hospital, Qinghai No.3 People's Hospital, Qinghai No.3 People's Hospital, Wuxi Fourth People's Hospital, Wuxi People's Hospital
- Publication date:
- 2026-02-04
- OpenAlex record:
- View
Get the weekly research newsletter
Stay current with peer-reviewed research without reading academic papers — one filtered digest, every Friday.